ReBio
3 known investors
Find your way into ReBio
120 people in our graph share verified history with the ReBio team — schools, employers, funds. One of them is your warm intro.
Noubar Afeyanunlockedknows Roi Raz · together at Moderna (overlapped)
×9knows the team · via Reichman University
knows the team · via Moderna
knows the team · via Harvard Business School Executive Education
ReBio develops targeted, locally delivered therapies for ocular oncology, using its proprietary SiSu conjugate platform to program drug exposure for eye diseases. Its lead program, RBP-01, is a SiSu-conjugated PKC inhibitor for uveal melanoma delivered via intravitreal injection, with additional programs targeting retinoblastoma, glaucoma, and post-op ocular inflammation.
Founders & leadership
RR
Roi RazinChief Executive OfficerPreviously chief financial officer at Trigone Pharma and senior director of investor relations at Moderna, following work as a pharma and biotech equity analyst at AtonRâ Partners. He earlier managed biotech portfolios at Adamas Capital Management/Mascall Management and spent six years at Barak Capital as an investment analyst and portfolio manager.
Investors · 3
In the news
Frequently asked questions
- What does ReBio do?
- ReBio develops targeted, locally delivered therapies for ocular oncology, using its proprietary SiSu conjugate platform to program drug exposure for eye diseases. Its lead program, RBP-01, is a SiSu-conjugated PKC inhibitor for uveal melanoma delivered via intravitreal injection, with additional programs targeting retinoblastoma, glaucoma, and post-op ocular inflammation.
- Who are ReBio's investors?
- ReBio's investors include Kinled Holding, SICTIC, WI Harper.